Notis-McConarty Edward’s Vertex Pharmaceuticals VRTX Stock Holding History

Notis-McConarty Edward’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.52M	Buy	7,885 +31	+0.4%	+$14.5K	1.75%	23
2025 Q4	$3.56M	Buy	7,854 +50	+0.6%	+$21.6K	1.65%	22
2025 Q3	$3.06M	Buy	7,804 +423	+6%	+$177K	1.42%	27
2025 Q2	$3.29M	Buy	7,381 +106	+1%	+$48.8K	1.6%	24
2025 Q1	$3.53M	Buy	7,275 +756	+12%	+$352K	1.81%	23
2024 Q4	$2.63M	Buy	6,519 +1,257	+24%	+$583K	1.27%	27
2024 Q3	$2.45M	Buy	5,262 +1,475	+39%	+$709K	1.11%	30
2024 Q2	$1.78M	Buy	3,787 +2,462	+186%	+$1.07M	0.7%	39
2024 Q1	$554K	Buy	+1,325	New	+$560K	0.22%	65

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Notis-McConarty Edward's VRTX Position: Q1 2026 in Review

Notis-McConarty Edward increased its Vertex Pharmaceuticals (VRTX) stake by 0.39% in Q1 2026, buying an estimated $14.5K and bringing the position to 7,885 shares worth $3.52M. The position accounts for 1.75% of the portfolio, ranked #23.

Notis-McConarty Edward first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $3.56M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Notis-McConarty Edward held 7,885 shares of Vertex Pharmaceuticals worth $3.52M as of Q1 2026.
Notis-McConarty Edward bought 31 Vertex Pharmaceuticals shares in Q1 2026, an estimated $14.5K.
Vertex Pharmaceuticals made up 1.75% of Notis-McConarty Edward's portfolio in Q1 2026, its #23 holding.
Notis-McConarty Edward first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Notis-McConarty Edward's Vertex Pharmaceuticals position peaked at $3.56M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Notis-McConarty Edward's 13F filing for Q1 2026, filed 8 May 2026.